beta
Trial Radar AI
Clinical Trial NCT06352281 for ITP - Immune Thrombocytopenia is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) Phase 1, Phase 2 10 Open-Label

Recruiting
Clinical Trial NCT06352281 is designed to study Treatment for ITP - Immune Thrombocytopenia. It is a Phase 1 Phase 2 interventional study that is recruiting, having started on 1 February 2024, with plans to enroll 10 participants. Led by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, it is expected to complete by 31 December 2027. The latest data from ClinicalTrials.gov was last updated on 22 July 2024.
Brief Summary
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
Detailed Description
This open label and single-arm study aims to evaluate the efficacy and safety of CAR-T cells therapy in patients with Chronic or Refractory Primary Immune Thrombocytopenia (ITP). After enrollment, a leukapheresis procedure will be performed to manufacture chimeric antigen receptor (CAR) modified T cells. Patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide, then the CAR-T cells w...Show More
Official Title

An Investigator-initiated Trial to Evaluate the Efficacy and Safety of CAR-T Cells Therapy in the Treatment of Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Conditions
ITP - Immune Thrombocytopenia
Other Study IDs
  • KM-007
NCT ID Number
NCT06352281
Start Date (Actual)
2024-02-01
Last Update Posted
2024-07-22
Completion Date (Estimated)
2027-12-31
Enrollment (Estimated)
10
Study Type
Interventional
PHASE
Phase 1
Phase 2
Status
Recruiting
Keywords
CAR-T
Immune Thrombocytopenia (ITP)
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalCAR-T Cells Therapy
Subjects who meet the enrollment conditions will receive intravenous infusion of CAR-T cells after lymphodepletion.
CAR-T cells
CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Portion of patients with response (R)
platelet count\>30x10\^9/L and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding
At least 2 weeks after infusion
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Portion of patients with complete response (CR)
platelet count\>100x10\^9/L, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding
At least 2 weeks after infusion
Portion of patients with relapse
platelet count below 30x10\^9/L or less than 2-fold increase of baseline platelet count or bleeding after treating effectively; platelet counts confirmed on at least 2 separate occasions approximately 1 day apart
At least 2 weeks after infusion
Time (in days) from treatment start to response (R)
Time calculated from infusion to the day when the response (R) criteria are achieved
At least 2 weeks after infusion
Time (in days) from treatment to complete response (CR)
Time calculated from infusion to the day when the complete response (CR) criteria are achieved
At least 2 weeks after infusion
Duration (in days) of response (R)
Time calculated from the day when the response (R) criteria are achieved, to the day when loss of response (R) criteria is achieved
At least 2 weeks after infusion
Incidence of adverse events(AE) after infusion
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.
Up to 12 months after infusion
Participation Assistant
Eligibility Criteria

Eligible Ages
Child, Adult, Older Adult
Minimum Age
8 Years
Eligible Sexes
All
  1. Willingness to complete the informed consent process and to comply with study procedures and visit schedule;
  2. Men and women aged 8-75;
  3. Participants diagnosed with chronic (>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP;
  4. The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP;
  5. Platelet count <30 x 109 / L;
  6. If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening);
  7. The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;
  8. Willingness to use effective and reliable methods of contraception throughout the entire study period;

  1. All subjects with diseases which may cause secondary immune thrombocytopenia
  2. Patients with preventive splenectomy;
  3. Hemostatic disorders other than chronic thrombocytopenia;
  4. Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study;
  5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts;
  6. Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy;
  7. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment;
  8. History of thrombosis or presence of significant risk factors for thrombosis;
  9. Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;
  10. Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal);
  11. Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;
  12. Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;
  13. Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections;
  14. Patients with severe history of allergy or allergic constitution;
  15. Pregnancy and lactation;
  16. History of mental illness and known alcohol/drug addiction;
  17. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;
  18. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China logo920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Study Central Contact
Contact: Sanbin Wang, Doctor, 13187424131, [email protected]
1 Study Locations in 1 Countries

Yunnan

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan, 650000, China
Sanbin Wang, Doctor, Contact, 13187424131, [email protected]
Recruiting